Related Experiment Video
Updated: Jun 6, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition
Published on: January 7, 2019
PTOV1 antagonizes MED25 in RAR transcriptional activation
Hye-Sook Youn1, Ui-Hyun Park, Eun-Joo Kim
1Department of Bioscience and Biotechnology, Institute of Bioscience, Sejong University, Seoul 143-747, Republic of Korea.
Abstract:
Retinoic acid (RA) plays a role in cancer therapy. However, its long-term treatment is hindered by the acquired resistance which is not fully understood. Our previous study indicated that the transcriptional activity of RA receptor (RAR) is enhanced by association of MED25 with CREB-binding protein (CBP) through the PTOV domain, which is also present in prostate tumor over-expressed protein 1 (PTOV1). Here, we show that MED25 and PTOV1 reciprocally regulate RAR transcriptional activity through competitive bindings to CBP and opposite regulation of CBP recruitment to the RA-responsive gene promoter. Finally, we demonstrate that MED25 and PTOV1 differentially modulate RA sensitivity in cancer cells depending on their expression levels, suggesting a potential molecular mechanism underlying RA resistance which frequently emerges during cancer treatments.
Insights
Retinoic acid (RA) therapy resistance in cancer may involve MED25 and PTOV1 proteins. These proteins competitively bind to CBP, affecting RA receptor activity and cancer cell sensitivity to RA treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Retinoic acid (RA) is a crucial therapeutic agent in cancer treatment.
- Acquired resistance limits the long-term efficacy of RA therapy, and its mechanisms remain incompletely understood.
- MED25 enhances Retinoic Acid Receptor (RAR) transcriptional activity via association with CREB-binding protein (CBP).
Purpose of the Study:
- To investigate the reciprocal regulation of RAR transcriptional activity by MED25 and prostate tumor over-expressed protein 1 (PTOV1).
- To elucidate the molecular mechanisms underlying retinoic acid resistance in cancer therapy.
- To determine how MED25 and PTOV1 expression levels influence cancer cell sensitivity to RA.
Main Methods:
- Investigated competitive binding interactions between MED25, PTOV1, and CBP.
- Analyzed the recruitment of CBP to RA-responsive gene promoters.
- Assessed the modulation of RA sensitivity in cancer cells based on MED25 and PTOV1 expression levels.
Main Results:
- MED25 and PTOV1 competitively bind to CBP, reciprocally regulating RAR transcriptional activity.
- These proteins exert opposing effects on CBP recruitment to RA-responsive gene promoters.
- Differential expression of MED25 and PTOV1 significantly modulates RA sensitivity in cancer cells.
Conclusions:
- MED25 and PTOV1 play a critical role in regulating RA sensitivity through competitive binding to CBP.
- Their opposing actions on CBP recruitment offer a potential molecular basis for acquired RA resistance during cancer treatment.
- Understanding these interactions may lead to strategies to overcome RA resistance in cancer therapy.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
RNA Polymerase II Accessory Proteins
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
